Can a man at 49 join clinical trials for prurigo nodularis?

Question

Hello doctor,

I am desperate for prurigo nodularis treatment guidance. Suffering for over four years with progressive disease now covering approximately 60 percent of the body surface area, including visible areas, which is affecting both professional and personal interactions.

I am a 49-year-old male with previous treatments including topical corticosteroids, intralesional corticosteroid injections, antihistamines, Gabapentin, limited response to Cyclosporine (discontinued due to hypertension), and narrowband ultraviolet B (UVB) phototherapy (discontinued after 40 sessions without improvement).

I was recently prescribed Thalidomide (Thalomid), but was denied insurance coverage because the monthly out-of-pocket cost is unaffordable. Constant itching continues to disrupt sleep despite various medication combinations. I have been reading about emerging Janus kinase (JAK) inhibitors and Dupilumab (Dupixent), showing promise in clinical trials.

Would participation in a clinical trial be appropriate given these extensive treatment failures? How are emerging treatments accessed before formal approval by the United States Food and Drug Administration (FDA) for this condition? I need guidance regarding the potential for referral to an academic medical center versus continuing with my local dermatologist, who seems to have exhausted conventional treatment options.

Kindly help.

Answer 1

Hello,

Welcome to icliniq.com.

I have read your query and understand your concerns. You have been struggling with severe prurigo nodularis for over four years. It now covers most of your body and significantly affects your sleep, work, and personal life, with no treatments providing substantial relief so far.

One option to consider is Dupilumab (Dupixent), which is approved for prurigo nodularis and has shown good results in many patients. It is also more likely to be covered by insurance than high-cost treatments like Thalidomide (Thalomid).

New treatments, such as Janus kinase (JAK) inhibitors, are still undergoing clinical trials and are not fully approved yet, but you may be a strong candidate for these, given your lack of response to previous therapies. Participating in a clinical trial can provide access to free treatment and specialized care. You can search for ongoing studies online by entering “prurigo nodularis.”

Another step is to consider seeking care at an academic medical center or university-affiliated hospital, where dermatology experts are experienced in managing rare and severe skin conditions. These centers often conduct trials and may offer early access to promising treatments.

Ask your current doctor for a referral. Moving forward, you should request a referral to a university hospital or skin specialist center, explore local clinical trials that you may qualify for, and speak with your doctor about newer treatments and any available support programs.

I hope this helps.

Thank you.